Total dividend bookyear 2018: € 0.000*

Final dividend

proposed amount
€ 0.000
announcement date
May 7, 2019
ex-coupon date
payment date

Dividend history

financial events

Company information

source: company website, January 2019

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

Dividend policy

Source: annual report 2017

We do not expect to pay cash dividends in the foreseeable future.